INDEPENDENT VERDICT
Propel(x) Syndicates LLC - VentureUs ScopeSys 2026 SPV is a particularly transparent example of how a modern syndication platform can convert a small group of accredited investors into one cap-table investment in an early-stage company. The April 24, 2026 Form D reports an exact $72,300 offering, the full $72,300 sold to eight investors on the same date as the first sale, a $5,000 minimum and Rule 506(b). Tim Kelly is the sole disclosed related person and signs as President. Unlike many opaque numbered Propel(x) series, this issuer tells investors nearly the entire transaction chain in its legal name: Propel(x) provides the SPV infrastructure, VentureUs identifies the syndicate relationship, and ScopeSys identifies the underlying company. Public VentureUs and ScopeSys materials independently confirm that VentureUs invested in ScopeSys, giving the portfolio-company link much stronger support than a simple name inference.
THE MOST IMPORTANT STORY IS THAT THE $72,300 FORM D IS ONLY ONE SMALL U.S. SYNDICATE SLICE OF A MUCH LARGER SCOPEsys FINANCING
ScopeSys publicly announced a CA$1.5 million seed round backed by UBC Venture Funds, Hextwo Capital, WUTIF Capital (VCC) Inc., VentureUs, Xavaav Capital and angel investors across Canada and the United States. The Propel(x) SPV's $72,300 should therefore not be presented as ScopeSys' total financing, nor should the company's CA$1.5 million financing be attributed entirely to Propel(x) or VentureUs. The SEC issuer is simply one investment conduit within the larger round. This distinction is unusually valuable for FilingDossier because it shows exactly how Form D data can understate the financing event visible at company level: a startup may close a substantially larger round while several individual funds, SPVs, venture firms and angels each contribute only one portion of the capital.
PROPEL(X) IS THE INFRASTRUCTURE LAYER, WHILE VENTUREUS IS THE INVESTMENT-SYNDICATE LAYER
Propel(x)'s current SPV offering explains its operating role in unusually concrete terms. The platform advertises end-to-end syndicate infrastructure including Delaware entity formation, EIN and CIK setup, investor onboarding, KYC/AML, subscription documentation, closings, fund flows, tax filings, distributions and ongoing administration. Propel(x) says SPV administration begins around $4,000 and scales with deal size, with the published fee capped at $12,000 for the standard product. That service description strongly explains why hundreds of Propel(x) entities appear as separate Form D issuers with the same Reno infrastructure and Tim Kelly as a repeated officer. VentureUs, by contrast, is the investment network whose official portfolio explicitly includes ScopeSys and whose partners include Jenn Wrenn Henry, Jonathan Kagle, Keith Laepple and Susan Preston. VentureUs publicly stated that it invested in ScopeSys after conducting diligence on the company. The two roles therefore should not be collapsed: Propel(x) administers the SPV architecture; VentureUs appears to originate or lead the investment thesis.
SCOPEsys PROVIDES FAR MORE TECHNICAL SUBSTANCE THAN THE FORM D ITSELF
ScopeSys is a Vancouver biotechnology instrumentation company spun out of the Leslie Lab at the University of British Columbia. Its core technology is Convex Lens-induced Confinement, or CLiC, a microscopy and analytics platform designed to observe RNA, DNA, proteins, nanoparticles and other biological systems at single-molecule or single-particle resolution. ScopeSys says its commercial focus includes genomic medicines and the development of RNA-, DNA- and nanoparticle-delivered therapeutics. Instead of relying only on ensemble averages, CLiC is designed to reveal heterogeneity at the individual molecule or particle level — including characteristics relevant to mRNA loading and nanoparticle drug formulations. The company traces the underlying technology to work by co-founder Sabrina Leslie, whose academic history includes UBC, UC Berkeley, Harvard and McGill. By 2026, ScopeSys described itself as commercial-stage and said the seed capital would accelerate the commercial launch of a benchtop analytical instrument and consumables.
THE COMPANY'S SCIENCE ALSO EXPLAINS WHY THIS IS NOT A GENERIC SOFTWARE-STYLE VENTURE BET
ScopeSys faces a different risk profile from many of the AI or SaaS companies found elsewhere on venture platforms. Its commercial outcome depends on hardware performance, microscopy workflows, reproducibility, customer adoption inside pharmaceutical and biotechnology R&D organizations, manufacturing of instruments and consumables, and whether single-particle analytics generates enough decision-making value to justify replacing or supplementing established analytical techniques. ScopeSys says early-access technology has already been placed with selected researchers and identifies partnerships or relationships involving UBC, McGill, Harvard and other institutions, but those scientific relationships should not be confused with recurring commercial revenue. Investors therefore need to separate validation of the technology from validation of the business model.
PROPEL(X)'S MUCH LARGER PORTFOLIO HISTORY SHOULD BE USED AS PLATFORM EVIDENCE, NOT AS SCOPEsys PERFORMANCE EVIDENCE
Propel(x) has been facilitating investments for years across biotechnology, computing, energy, industrial technology, transportation and other deep-tech sectors. Its public portfolio includes companies such as Oisin Biotechnologies, HealX, SafeTraces, Cerebri AI and many others, while historical SEC records stretch back to early company-specific vehicles such as Propel (Positron Dynamics) LLC in 2016 and hundreds of later numbered series. This establishes that the ScopeSys SPV is part of an established syndication mechanism rather than an isolated new issuer. It does not mean ScopeSys investors own any interest in those other companies, and past Propel(x) portfolio exits or successes cannot be transferred to the economics of this SPV.
FINAL ASSESSMENT
The VentureUs ScopeSys SPV contains at least eight unusually strong evidence points: its exact $72,300 offering was fully sold; eight investors participated; the minimum was only $5,000; the issuer name directly identifies VentureUs and ScopeSys; VentureUs independently confirms its ScopeSys investment; ScopeSys independently confirms a CA$1.5 million seed round; the broader round names multiple other institutional and angel investors; and ScopeSys is a documented UBC spinout commercializing CLiC single-molecule analytics. The central diligence question is therefore not whether the underlying company can be identified — it can — but what security the SPV purchased, at what valuation, how Propel(x) administration fees and any VentureUs carry affect investor economics, and what percentage of ScopeSys the $72,300 vehicle ultimately owns.
SEC SNAPSHOT
Issuer: Propel(x) Syndicates LLC - VentureUs ScopeSys 2026 SPV CIK: 0002130689 SEC Form: Form D Accession No.: 0002130689-26-000001 Filing Date: April 24, 2026 Formation Year: 2026 Jurisdiction: Delaware Principal Address: 1 East Liberty, Suite 600, Reno, NV 89501 Telephone: 833-277-6735 ext. 2 Industry: Pooled Investment Fund Fund Classification: Venture Capital Fund Investment Company Registered: No Investment Company Act Section 3(c) Exclusion Selected: No Offering Exemption: Rule 506(b) Security Type: Pooled Investment Fund Interests Offering Amount: $72,300 Amount Sold: $72,300 Remaining To Be Sold: $0 Offering Sold Percentage: 100% Investors: 8 Minimum Investment: $5,000 First Sale: April 24, 2026 Offering Duration Over One Year: No Business Combination Transaction: No Sales Commissions: $0 Finder's Fees: $0 Related Person: Tim Kelly Related Person Role: Executive Officer Signer: Tim Kelly Signer Title: President
SPV / PLATFORM ROLE PENETRATION
SPV Infrastructure Platform: Propel(x) Official Website: propelx.com SPV Entity Formation: YES EIN Setup: YES CIK Setup: YES Investor Onboarding: YES KYC / AML Support: YES Subscription Documentation: YES Closing Administration: YES Fund-Flow Administration: YES Tax Filing Support: YES Distribution Administration: YES Ongoing SPV Administration: YES
Published SPV Starting Cost: Approximately $4,000 Published Standard Pricing Cap: Approximately $12,000 Exact Fee Charged to This ScopeSys Vehicle: NOT PUBLICLY CONFIRMED
Propel(x) Role Proven to Equal Investment Selection Role: NO Propel(x) Role Proven to Equal VentureUs Role: NO
VENTUREUS PENETRATION
Investment Network: VentureUs Official Website: ventureus.org
Managing Partners: Jenn Wrenn Henry Jonathan Kagle Keith Laepple
Venture Partner: Susan Preston
ScopeSys Listed in Official VentureUs Portfolio: YES VentureUs Publicly States It Invested in ScopeSys: YES VentureUs Diligence Commentary Publicly Documented: YES VentureUs Relationship Reflected Directly in SPV Legal Name: YES
Other VentureUs Portfolio Examples Publicly Listed: Dream Photonics n2uitive Nowadays Roby Sky Acres Verdi
All VentureUs Portfolio Companies Held by ScopeSys SPV: NO
SCOPEsys COMPANY PENETRATION
Underlying Company: ScopeSys Official Website: scopesys.ca Headquarters: Vancouver, British Columbia, Canada Founded: 2017 Origin: University of British Columbia / Leslie Lab spinout Sector: Biotechnology / Life Sciences Instrumentation Core Technology: Convex Lens-induced Confinement (CLiC) Technology Category: Single-molecule / single-particle analytics
Applications Publicly Described: RNA analysis DNA analysis Protein analysis Nanoparticle analysis mRNA / lipid nanoparticle characterization Genomic medicine development Drug formulation development Vaccine development
Company Development Stage in Official Materials: Commercial-stage Commercial Product Direction: Benchtop analytical instrument plus consumables Early-Access Technology Placements: YES
Founder / Director: Sabrina Leslie, Ph.D.
Academic / Scientific Background Includes: University of British Columbia UC Berkeley Harvard McGill
SCOPEsys FINANCING PENETRATION
2026 Seed Round Publicly Announced: CA$1.5 million Approximate U.S. Dollar Equivalent at Announcement: Roughly US$1.1 million, depending on exchange rate
Announced Investors Include: UBC Venture Funds Hextwo Capital WUTIF Capital (VCC) Inc. VentureUs Xavaav Capital Canadian angel investors U.S. angel investors
Propel(x) ScopeSys SPV Amount: US$72,300 SPV Investors: 8
SPV Amount Equal to Entire ScopeSys Seed Round: NO Propel(x) Sole Investor in ScopeSys Round: NO VentureUs Sole Investor in ScopeSys Round: NO $72,300 Proven to Represent VentureUs' Entire Economic Exposure: NO
Interpretation: The Propel(x) issuer represents one syndicate allocation inside a larger multi-investor financing.
PLATFORM HISTORY PENETRATION
Historical Propel(x) Company-Specific Vehicle: Propel (Positron Dynamics) LLC CIK: 0001667936 SEC Filing Year: 2016 Managing Member Identified Historically: Propel(x) Advisors LLC
Later Propel(x) Structure: Propel(x) Syndicates LLC - numbered Series vehicles Examples: Series 4281 Series 7845 Series 8481 Series 9230
2026 Named Syndicate Structures Also Exist: VentureUs ScopeSys 2026 SPV VentureUs Dream Photonics 2026 Pre-Seed SPV Grep VC Surgimatix
Repeated Officer: Tim Kelly
Historical Address: 300 E. 2nd Street, Suite 1510, Reno
Current 2026 Address: 1 East Liberty, Suite 600, Reno
Platform Address Changed: YES Platform Syndicate Model Continued: YES
RECENT NAMED-SPV EVIDENCE
VentureUs Dream Photonics 2026 Pre-Seed SPV: SEC Filing Confirmed: YES Tim Kelly Signer: YES Same Propel(x) Platform: YES
Grep VC Surgimatix: SEC Filing Date: September 18, 2026 Same Reno Address: YES Tim Kelly Relationship: YES Venture Capital Fund Classification: YES
Implication: Propel(x) supports multiple independent syndicate leads rather than acting as one single venture fund with one portfolio.
WEBSITE / ENTITY PENETRATION
Propel(x) Official Website Confirmed: YES Propel(x) Current SPV Service Confirmed: YES Tim Kelly Propel(x) Team / Advisor Relationship Confirmed: YES VentureUs Official Website Confirmed: YES ScopeSys Official Website Confirmed: YES ScopeSys VentureUs Relationship Confirmed: YES ScopeSys CA$1.5M Seed Round Confirmed: YES ScopeSys UBC Spinout History Confirmed: YES ScopeSys CLiC Technology Confirmed: YES Specific SPV Security Type in ScopeSys Confirmed: NO ScopeSys Valuation for SPV Confirmed: NO SPV Ownership Percentage Confirmed: NO SPV Carry Confirmed: NO SPV Management Fee Confirmed: NO SPV Administrator Beyond Propel(x) Platform Role: Not separately identified Fund Auditor Confirmed: NO Custodian Confirmed: NO
CORE INVESTOR QUESTIONS
What exact ScopeSys security did the SPV purchase Was the investment SAFE, preferred equity, common equity or convertible debt What pre-money and post-money valuation applied Was the $72,300 invested directly into ScopeSys or through another Canadian or U.S. entity How does the SPV participate in ScopeSys' CA$1.5 million seed round Did VentureUs invest separately in addition to this SPV Did Propel(x) or the syndicate lead contribute capital What percentage of ScopeSys does this SPV own on a fully diluted basis What pro rata rights does the SPV receive What information rights do the eight investors receive What administration fee did Propel(x) charge Does VentureUs receive carried interest Are organizational expenses deducted before capital reaches ScopeSys How are Canadian tax and cross-border securities issues handled What happens if ScopeSys requires a larger Series A before commercial scale What instrument and consumable gross margins are targeted How many commercial or early-access systems have been deployed What portion of ScopeSys revenue is recurring consumables versus instrument sales How reproducible is CLiC outside specialist academic labs What competing single-molecule or nanoparticle analytics platforms exist Who manufactures the commercial instrument What regulatory requirements apply to intended pharmaceutical-development workflows What exit path is expected for a small private-company SPV with no secondary liquidity
PRIMARY EVIDENCE REVIEWED
SEC Form D for Propel(x) Syndicates LLC - VentureUs ScopeSys 2026 SPV filed April 24, 2026. SEC filing confirming the exact $72,300 offering, $72,300 sold, eight investors, $5,000 minimum and Rule 506(b). Propel(x) official SPV / syndicate administration materials. Propel(x) official company and team materials. Propel(x) official portfolio and historical investment materials. Historical SEC Form D for Propel (Positron Dynamics) LLC. SEC Form D records for numbered Propel(x) Syndicates series. SEC filing for VentureUs Dream Photonics 2026 Pre-Seed SPV. September 2026 SEC filing for Propel(x) Syndicates LLC - Grep VC Surgimatix. VentureUs official portfolio and team materials. VentureUs public statement confirming investment in ScopeSys. ScopeSys official website. ScopeSys official technology and team materials. ScopeSys public announcement of its CA$1.5 million seed financing. Independent 2026 company reporting used to cross-check ScopeSys' financing and commercial-stage development.
IMPORTANT FORM D NOTICE
Propel(x) Syndicates LLC - VentureUs ScopeSys 2026 SPV's April 24, 2026 Form D reports a $72,300 offering fully sold to eight investors. ScopeSys separately announced a CA$1.5 million seed financing involving VentureUs and several other investors. The two amounts measure different things and should not be combined or substituted for one another: the Form D amount belongs to this specific U.S. SPV, while CA$1.5 million is the broader company financing. Propel(x)'s administration platform, VentureUs' investment role and ScopeSys' operating business are separate layers of the transaction. Form D is an exempt-offering notice and does not constitute SEC approval or endorsement of Propel(x), VentureUs, ScopeSys or the underlying technology.